(1H-benzo[d]imidazol-2-yl)(p-tolyl)methanone | 56969-32-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1H-benzo[d]imidazol-2-yl)(p-tolyl)methanone
• 英文别名: (1H-benzoimidazol-2-yl)-p-tolyl-methanone；1H-benzimidazole-2-yl(4-methylphenyl)methanone；(1H-Benzimidazol-2-yl)(4-methylphenyl)methanone；1H-benzimidazol-2-yl-(4-methylphenyl)methanone
• CAS: 56969-32-5
• 化学式: C₁₅H₁₂N₂O
• 分子量: 236.273
• InChiKey: QJTSVDFEFRDKJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  462.9±38.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1H-benzo[d]imidazol-2-yl)(p-tolyl)methanone 在 caesium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二甲基亚砜 、 丙酮 为溶剂， 生成 (4-Methylphenyl)(1-vinyl-1H-benzimidazol-2-yl)methanone
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators

  摘要：

  In our search for new PPAR alpha/gamma agonists, we designed and synthesized a series of benzoylazole-based carboxylic acids. Compound 9 showed potent PPAR gamma partial agonistic activity with modest PPAR alpha agonistic activity. The sodium salt of 9 (9Na) demonstrated potent efficacy in lowering both blood glucose and lipids in an animal model without causing significant body weight gain, a well-known side effect associated with PPAR gamma full agonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.032
• 作为产物：
  描述：

  对甲基苯乙酸 在 双(乙腈)氯化钯(II) 、 cesium pivalate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 46.0h， 生成 (1H-benzo[d]imidazol-2-yl)(p-tolyl)methanone
  参考文献：
  名称：

  苯并唑衍生物的无金属需氧氧化†

  摘要：

  2-苄基苯并噻唑和苯并咪唑在空气和碱性条件下容易氧化，以高收率得到相应的酮。指某东西的用途醋酸钯 作为催化剂，收效甚微，甚至在某些情况下收率低得多。

  DOI：

  10.1039/c3ob27404g

文献信息

• Selective synthesis of (1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)(phenyl)methanone and quinoxaline from aromatic aldehyde and <i>o</i>-phenylenediamine
  作者：Zhenzhen Zhan、Haojie Ma、Xinfeng Cui、Pengbo Jiang、Jinghong Pu、Yixin Zhang、Guosheng Huang

  DOI：10.1039/c9ob00531e

  日期：——

  We have designed a general, inexpensive, and versatile method for the synthesis of (1H-benzo[d]imidazol-2-yl)(phenyl)methanone and the formation of C–N bonds via an aromatic aldehyde and o-phenylenediamine. In the presence of N,N-dimethylformamide/sulfur, (1H-benzo[d]imidazol-2-yl)(phenyl)methanone was obtained; however, in the absence of sulfur, quinoxaline was obtained in 1,4-dioxane. A wide range

  我们设计了一种通用，廉价且通用的方法，用于合成（1 H-苯并[ d ]咪唑-2-基）（苯基）甲酮并通过芳香醛和邻苯二胺形成C–N键。在N，N-二甲基甲酰胺/硫的存在下，得到（1H-苯并[ d ]咪唑-2-基）（苯基）甲酮。然而，在不存在硫的情况下，在1,4-二恶烷中获得了喹喔啉。在温和的条件下获得了广泛的喹喔啉和（1 H-苯并[ d ]咪唑-2-基）（苯基）亚甲酮。
• Novel Heteroaryl Derivative
  申请人：Takahashi Yoko

  公开号：US20080167306A1

  公开（公告）日：2008-07-10

  A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. wherein the ring Z is an optionally substituted heteroaryl, W 4 is a single bond, lower alkylene, etc., Ar 2 is an optionally substituted aryl, etc., W 3 is a single bond, lower alkylene, etc., Ar 1 is an optionally substituted arylene, etc., each of W 1 and W 2 is an optionally substituted lower alkylene, etc., and R 1 is carboxyl, an alkoxycarbonyl.

  下列式子（1）的化合物，或其前药或其药学上可接受的盐，被用作糖尿病药物或预防药物，或血糖调节剂，或高脂血症等治疗剂。其中，环Z是可选取代的杂芳基，W4是单键，低碳链等，Ar2是可选取代的芳基等，W3是单键，低碳链等，Ar1是可选取代的芳烃基等，W1和W2是可选取代的低碳链等，R1是羧基，烷氧羰基等。
• HETEROARYL DERIVATIVES
  申请人：TAKAHASHI Yoko

  公开号：US20100286144A1

  公开（公告）日：2010-11-11

  A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. wherein the ring Z is an optionally substituted heteroaryl, W 4 is a single bond, lower alkylene, etc., Ar 2 is an optionally substituted aryl, etc., W 3 is a single bond, lower alkylene, etc., Ar 1 is an optionally substituted arylene, etc., each of W 1 and W 2 is an optionally substituted lower alkylene, etc., and R 1 is carboxyl, an alkoxycarbonyl.

  以下式子（1）的化合物，或其前药或药学上可接受的盐，可用作糖尿病药物、预防药物、血糖调节剂或高脂血症等治疗剂。 其中，环Z是可选取的取代杂环基，W4是单键，低碳烷基等，Ar2是可选取的取代芳基等，W3是单键，低碳烷基等，Ar1是可选取的取代芳烃基等，W1和W2各自是可选取的取代低碳烷基等，R1是羧基，烷氧羰基等。
• NOVEL HETEROARYL DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1647546B1

  公开（公告）日：2012-05-02
• The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors
  作者：Moon H. Kim、Amy Lew Tsuhako、Erick W. Co、Dana T. Aftab、Frauke Bentzien、Jason Chen、Wei Cheng、Stefan Engst、Levina Goon、Rhett R. Klein、Donna T. Le、Morrison Mac、Jason J. Parks、Fawn Qian、Monica Rodriquez、Thomas J. Stout、Jeffrey H. Till、Kwang-Ai Won、Xiang Wu、F. Michael Yakes、Peiwen Yu、Wentao Zhang、Yeping Zhao、Peter Lamb、John M. Nuss、Wei Xu

  DOI：10.1016/j.bmcl.2012.06.029

  日期：2012.8

  Variously substituted indolin-2-ones were synthesized and evaluated for activity against KDR, Flt-1, FGFR-1 and PDGFR. Extension at the 5-position of the oxindole ring with ethyl piperidine (compound 7i) proved to be the most beneficial for attaining both biochemical and cellular potencies. Further optimization of 7i to balance biochemical and cellular potencies with favorable ADME/ PK properties led to the identification of 8h, a compound with a clean CYP profile, acceptable pharmacokinetic and toxicity profiles, and robust efficacy in multiple xenograft tumor models. (c) 2012 Elsevier Ltd. All rights reserved.